Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Ciccullo, Arturo; Giuliano, Gabriele; Segala, Francesco Vladimiro; Taddei, Eleonora; Farinacci, Damiano; Pallavicini, Federica

doi:10.1007/s15010-019-01379-2

Cited by 7 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent anecdotal reports of the efficacy of dalbavancin in bloodstream infections have been published [14][15][16][17][18][19][20][21][22][23][24][25][26]. A retrospective cohort study conducted in the University Hospital of Vienna between January 2015 and December 2016 showed that microbiological and clinical success was achieved in 93% (25/27) of patients who received dalbavancin either as primary or sequential treatment for infective endocarditis.…”

Section: Discussionmentioning

confidence: 99%

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

et al. 2021

View full text Add to dashboard Cite

Introduction: Dalbavancin is a long-acting, bactericidal, lipoglycopeptide antibiotic approved by the US Food and Drug Administration and the European Medicines Agency for treatment of acute bacterial skin and skin structure infections in adults, with potent activity against Gram-positive pathogens, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Here we describe the clearance and clinical outcomes of patients with S. aureus bacteremia in five clinical trials of skin and skin structure infections or catheter-related bloodstream infections that evaluated the efficacy and safety of dalbavancin. Methods: Patients with uncomplicated S. aureus bacteremia identified in blood cultures drawn at baseline (before study drug) with at least one follow-up blood culture are described from four phase 3 trials in skin and skin structure infections and one phase 2 catheter-related infection study. Dalbavancin was administered as a single-dose (1500 mg intravenous [IV]) or a twodose regimen (1000 mg IV on day 1, 500 mg IV on day 8). Comparators included vancomycin IV or linezolid IV/oral for 10-14 days. Results: All 39 patients (100%) who received dalbavancin, including 8 patients on the singledose regimen, had clearance of bacteremia versus 19/20 patients (95%) treated with comparators (vancomycin or linezolid). At end of treatment, 33/36 dalbavancin-treated patients (92%) achieved clinical success versus 18/23 patients (78%) treated with comparators. Conclusions: All 39 patients with uncomplicated S. aureus bacteremia treated with dalbavancin (single-or two-dose regimen) and with follow-up blood cultures had clearance of their bloodstream infection. Clinical response rates Pedro L. Gonzalez and Urania Rappo contributed equally to the work.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Dalbavancin is the first long-acting anti-infective approved by FDA, that has been recently investigated with encouraging results for in-and off-label indications [13,14,16,17,22,[24][25][26][27][28][29][30][31][32]; clinical trials on osteomyelitis and complicated BSI are still ongoing (NCT03091439-NCT03426761-NCT03148756-NCT02940730).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

Bai

Aldieri

Cattelan

et al. 2020

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…Ten observational studies, one case series, and six case reports 31,[33][34][35][36][37][38][39][40][41][46][47][48][49][50][51][52] assessed the efficacy and safety of dalbavancin for the treatment of bloodstream infections (BSIs) and vascular infections (Table 3). Overall, 144 patients affected by BSIs or vascular infections were treated with dalbavancin, resulting in a clinical success of 81.3%.…”

Section: Bloodstream and Vascular Infectionsmentioning

confidence: 99%

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Gatti

Andreoni

Pea

et al. 2021

DDDT

View full text Add to dashboard Cite

Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy in osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections. This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharmacodynamic profile) until April 2021 was performed on the PubMed-MEDLINE database. As for other novel antibiotics, a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin as well. The promising efficacy in challenging scenarios (i.e., osteomyelitis, endocarditis, prosthetic joint infections), coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. This makes dalbavancin valuable in the current COVID-19 scenario, in which hospitalization and territorial medicine empowerment are unavoidable.

show abstract

Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Cited by 7 publications

References 5 publications

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Contact Info

Product

Resources

About